{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:56:40Z","timestamp":1793321800222,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background and aim<\/jats:title>\n            <jats:p>Cushing\u2019s disease (CD) is associated with phenotypic traits and comorbidities that may persist after the normalization of cortisol levels. Medical therapy is usually given in recurrent or persistent CD after transsphenoidal surgery. We aimed to investigate the impact of long-term normalization of daily cortisol secretion on clinical picture and cardiometabolic comorbidities, comparing surgical remission to medical treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Monocentric retrospective study, two- and five-years observation. Sixty CD patients, with sustained normal 24-h urinary free cortisol (UFC) levels, divided group 1 (surgical remission, <jats:italic>n<\/jats:italic>\u2009=\u200936) and group 2 (medical remission, <jats:italic>n<\/jats:italic>\u2009=\u200924).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Patients were different after achieving eucortisolism with surgery or medical treatment. Phenotypic traits: round face, dorsocervical fat pad, and bruisability persisted more prominently in the group 2, however abdominal obesity and muscle weakness persisted in both groups, especially in those patients with increased late-night salivary cortisol (LNSC). Hypertension: greater improvement was observed in group 1 (-31% vs. -5%, <jats:italic>p<\/jats:italic>\u2009=\u20090.04). Diabetes: less prevalent in group 1 after 2 years (2\/36 vs. 9\/24, <jats:italic>p<\/jats:italic>\u2009=\u20090.002), with a corresponding reduction in glucose-lowering treatments and persistence of impaired LNSC in diabetic patients (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Dyslipidemia: remained widespread in both groups, with minimal improvement over time (-22% in surgical and \u2212\u20096% in medical cohort).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Surgical remission leads to faster and sustained improvements in clinical phenotype. However, obesity, arterial hypertension, and dyslipidemia do not completely revert in five years, especially during medical treatment. Most comorbidities persist despite UFC normalization, due to impaired LNSC: the recovery of cortisol rhythms confirms the remission of hypercortisolism.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s40618-025-02572-x","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T16:01:41Z","timestamp":1743264101000},"page":"1597-1610","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Cardiometabolic complications after Cushing\u2019s disease remission"],"prefix":"10.1007","volume":"48","author":[{"given":"Irene","family":"Tizianel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Lizzul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Mondin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Voltan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Mazzeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Scaroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Barbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1456-8716","authenticated-orcid":false,"given":"Filippo","family":"Ceccato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"2572_CR1","doi-asserted-by":"publisher","unstructured":"Fleseriu M et al (2021) Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update, Dec. 01, Elsevier Ltd. https:\/\/doi.org\/10.1016\/S2213-8587(21)00235-7","DOI":"10.1016\/S2213-8587(21)00235-7"},{"key":"2572_CR2","doi-asserted-by":"publisher","unstructured":"Gadelha M, Gatto F, Wildemberg LE, Fleseriu M Cushing\u2019s syndrome. Dec 09 2023 Elsevier B V https:\/\/doi.org\/10.1016\/S0140-6736(23)01961-X","DOI":"10.1016\/S0140-6736(23)01961-X"},{"key":"2572_CR3","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae517","author":"F Ceccato","year":"2024","unstructured":"Ceccato F et al (2024) Clinical and biochemical data for the diagnosis of endogenous hypercortisolism: the \u2018cushingomic\u2019 approach. J Clin Endocrinol Metab Jul. https:\/\/doi.org\/10.1210\/clinem\/dgae517","journal-title":"J Clin Endocrinol Metab Jul"},{"key":"2572_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)00086-3","author":"R Pivonello","year":"2016","unstructured":"Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BMK, Colao A (2016) Complications of Cushing\u2019s syndrome: state of the Art. Lancet Publishing Group. https:\/\/doi.org\/10.1016\/S2213-8587(16)00086-3","journal-title":"Lancet Publishing Group"},{"issue":"7","key":"2572_CR5","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S2213-8587(16)30005-5","volume":"4","author":"RN Clayton","year":"2016","unstructured":"Clayton RN et al (2016) Mortality in patients with Cushing\u2019s disease more than 10 years after remission: A multicentre, multinational, retrospective cohort study. Lancet Diabetes Endocrinol 4(7):569\u2013576. https:\/\/doi.org\/10.1016\/S2213-8587(16)30005-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2572_CR6","doi-asserted-by":"publisher","DOI":"10.1210\/er.2013-1048","author":"R Pivonello","year":"2015","unstructured":"Pivonello R, De Leo M, Cozzolino A, Colao A (2015) The treatment of Cushing\u2019s disease. Endocr Soc. https:\/\/doi.org\/10.1210\/er.2013-1048","journal-title":"Endocr Soc"},{"key":"2572_CR7","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0883","author":"S Petersenn","year":"2015","unstructured":"Petersenn S et al (2015) Outcomes in patients with Cushing\u2019s disease undergoing transsphenoidal surgery: Systematic review assessing criteria used to define remission and recurrence. BioScientifica Ltd. https:\/\/doi.org\/10.1530\/EJE-14-0883","journal-title":"BioScientifica Ltd"},{"issue":"6","key":"2572_CR8","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s11102-018-0897-z","volume":"21","author":"LHA Broersen","year":"2018","unstructured":"Broersen LHA, Jha M, Biermasz NR, Pereira AM, Dekkers OM (2018) Effectiveness of medical treatment for Cushing\u2019s syndrome: a systematic review and meta-analysis. Pituitary 21(6):631\u2013641. https:\/\/doi.org\/10.1007\/s11102-018-0897-z","journal-title":"Pituitary"},{"key":"2572_CR9","doi-asserted-by":"publisher","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP (2008) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61(4): 344\u2013349. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.11.008","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"2572_CR10","doi-asserted-by":"publisher","unstructured":"Ceccato F (2024) The burden Of Cushing\u2019s disease cardiometabolic comorbidities: comparison between surgical remission and long-term eucortisolism with medical treatment. Repository of the University of Padova. https:\/\/doi.org\/10.25430\/researchdata.cab.unipd.it.00001350","DOI":"10.25430\/researchdata.cab.unipd.it.00001350"},{"issue":"5","key":"2572_CR11","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s11102-016-0729-y","volume":"19","author":"M Barbot","year":"2016","unstructured":"Barbot M et al (2016) Second-line tests in the differential diagnosis of ACTH-dependent Cushing\u2019s syndrome. Pituitary 19(5):488\u2013495. https:\/\/doi.org\/10.1007\/s11102-016-0729-y","journal-title":"Pituitary"},{"key":"2572_CR12","unstructured":"ISO 15189:2012 Medical laboratories \u2014 Requirements for quality and competence. Published 2022. Accessed October 10 (2023) https:\/\/www.iso.org\/standard\/56115.html"},{"issue":"1","key":"2572_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EJE-14-0061","volume":"171","author":"F Ceccato","year":"2014","unstructured":"Ceccato F et al (2014) The diagnostic performance of urinary free cortisol is better than the cortisol: cortisone ratio in detecting de Novo Cushing\u2019s syndrome: the use of a LC-MS\/MS method in routine clinical practice. Eur J Endocrinol 171(1):1\u20137. https:\/\/doi.org\/10.1530\/EJE-14-0061","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2572_CR14","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1530\/EJE-12-0534","volume":"167","author":"F Ceccato","year":"2012","unstructured":"Ceccato F et al (2012) Assessment of glucocorticoid therapy with salivary cortisol in secondary adrenal insufficiency. Eur J Endocrinol 167(6):769\u2013776. https:\/\/doi.org\/10.1530\/EJE-12-0534","journal-title":"Eur J Endocrinol"},{"key":"2572_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.cca.2015.10.004","volume":"451","author":"G Antonelli","year":"2015","unstructured":"Antonelli G, Ceccato F, Artusi C, Marinova M, Plebani M (2015) Salivary cortisol and cortisone by LC-MS\/MS: Validation, reference intervals and diagnostic accuracy in Cushing\u2019s syndrome. Clinica Chimica Acta 451:247\u2013251. https:\/\/doi.org\/10.1016\/j.cca.2015.10.004","journal-title":"Clinica Chimica Acta"},{"issue":"8","key":"2572_CR16","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s40618-020-01197-6","volume":"43","author":"F Ceccato","year":"2020","unstructured":"Ceccato F et al (2020) Dexamethasone measurement during low-dose suppression test for suspected hypercortisolism: threshold development with and validation. J Endocrinol Invest 43(8):1105\u20131113. https:\/\/doi.org\/10.1007\/s40618-020-01197-6","journal-title":"J Endocrinol Invest"},{"key":"2572_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2005.01.010","volume-title":"The metabolic syndrome and cardiovascular risk in Cushing\u2019s syndrome","author":"R Pivonello","year":"2005","unstructured":"Pivonello R, Faggiano A, Lombardi G, Colao A (2005) The metabolic syndrome and cardiovascular risk in Cushing\u2019s syndrome. W.B. Saunders. https:\/\/doi.org\/10.1016\/j.ecl.2005.01.010"},{"issue":"5","key":"2572_CR18","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2013-3628","volume":"99","author":"F Castinetti","year":"2014","unstructured":"Castinetti F et al (2014) Ketoconazole in Cushing\u2019s disease: is it worth a try. J Clin Endocrinol Metab 99(5):1623\u20131630. https:\/\/doi.org\/10.1210\/jc.2013-3628","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2572_CR19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11102-013-0475-3","volume":"17","author":"M Barbot","year":"2014","unstructured":"Barbot M et al (2014) Combination therapy for Cushing\u2019s disease: Effectiveness of two schedules of treatment. Should we start with cabergoline or ketoconazole? Pituitary 17(2):109\u2013117. https:\/\/doi.org\/10.1007\/s11102-013-0475-3","journal-title":"Pituitary"},{"key":"2572_CR20","doi-asserted-by":"crossref","unstructured":"Colao A et al (1999) Persistence of Increased Cardiovascular Risk in Patients with Cushing\u2019s Disease after Five Years of Successful Cure,., [Online]. Available: https:\/\/academic.oup.com\/jcem\/article\/84\/8\/2664\/2864186","DOI":"10.1210\/jc.84.8.2664"},{"key":"2572_CR21","doi-asserted-by":"publisher","unstructured":"Ceccato F et al (2017) Sep., Body Composition is Different after Surgical or Pharmacological Remission of Cushing\u2019s Syndrome: A Prospective DXA Study, Hormone and Metabolic Research, vol. 49, no. 9, pp. 660\u2013666. https:\/\/doi.org\/10.1055\/s-0043-115008","DOI":"10.1055\/s-0043-115008"},{"issue":"2","key":"2572_CR22","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1007\/s12020-016-0914-9","volume":"55","author":"V Guarnotta","year":"2017","unstructured":"Guarnotta V et al (2017) The degree of urinary hypercortisolism is not correlated with the severity of cushing\u2019s syndrome. Endocrine 55(2):564\u2013572. https:\/\/doi.org\/10.1007\/s12020-016-0914-9","journal-title":"Endocrine"},{"issue":"3","key":"2572_CR23","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1365-2265.2011.04055.x","volume":"75","author":"R Giordano","year":"2011","unstructured":"Giordano R et al (2011) Metabolic and cardiovascular outcomes in patients with Cushing\u2019s syndrome of different aetiologies during active disease and 1 year after remission. Clin Endocrinol (Oxf) 75(3):354\u2013360. https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04055.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2572_CR24","doi-asserted-by":"publisher","unstructured":"Jha S, Sinaii N, McGlotten RN, Nieman LK (2020) Remission of hypertension after surgical cure of Cushing\u2019s syndrome. Clin Endocrinol (Oxf), 92(20): 124\u2013130. https:\/\/doi.org\/10.1111\/cen.14129","DOI":"10.1111\/cen.14129"},{"issue":"1","key":"2572_CR25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s12020-018-1819-6","volume":"64","author":"MH Schernthaner-Reiter","year":"2019","unstructured":"Schernthaner-Reiter MH et al (2019) Factors predicting long-term comorbidities in patients with Cushing\u2019s syndrome in remission. Endocrine 64(1):157\u2013168. https:\/\/doi.org\/10.1007\/s12020-018-1819-6","journal-title":"Endocrine"},{"issue":"2","key":"2572_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1530\/EJE-19-0695","volume":"182","author":"J Newell-Price","year":"2020","unstructured":"Newell-Price J et al (2020) Use of late-night salivary cortisol to monitor response to medical treatment in Cushing\u2019s disease. Eur J Endocrinol 182(2):207\u2013217. https:\/\/doi.org\/10.1530\/EJE-19-0695","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2572_CR27","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s11102-023-01343-2","volume":"26","author":"A Mondin","year":"2023","unstructured":"Mondin A et al (2023) Complications and mortality of Cushing\u2019s disease: report on data collected over a 20-year period at a referral centre. Pituitary 26(5):551\u2013560. https:\/\/doi.org\/10.1007\/s11102-023-01343-2","journal-title":"Pituitary"},{"issue":"1","key":"2572_CR28","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s12020-018-1669-2","volume":"62","author":"M Barbot","year":"2018","unstructured":"Barbot M et al (2018) Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushing\u2019s disease. Endocrine 62(1):207\u2013214. https:\/\/doi.org\/10.1007\/s12020-018-1669-2","journal-title":"Endocrine"},{"issue":"1","key":"2572_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40618-021-01605-5","volume":"45","author":"E Ferrante","year":"2022","unstructured":"Ferrante E et al (2022) Evaluation of procoagulant imbalance in Cushing\u2019s syndrome after short- and long-term remission of disease. J Endocrinol Invest 45(1):9\u201316. https:\/\/doi.org\/10.1007\/s40618-021-01605-5","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"2572_CR30","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/cen.12299","volume":"80","author":"M Zilio","year":"2014","unstructured":"Zilio M, Barbot M, Ceccato F, Camozzi V, Bilora F, Casonato A, Frigo AC, Albiger N, Daidone V, Mazzai L, Mantero F, Scaroni C (2014) Diagnosis and complications of Cushing\u2019s disease: gender-related differences. Clin Endocrinol (Oxf) 80(3):403\u2013410. https:\/\/doi.org\/10.1111\/cen.12299","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2572_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s40618-023-02128-x","volume":"47","author":"M Detomas","year":"2024","unstructured":"Detomas M, Deutschbein T, Tamburello M, Chifu I, Kimpel O, Sbiera S, Kroiss M, Fassnacht M, Altieri B (2024) Erythropoiesis in Cushing syndrome: sex-related and subtype-specific differences. Results from a monocentric study. J Endocrinol Invest 47(1):101\u2013113. https:\/\/doi.org\/10.1007\/s40618-023-02128-x","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"2572_CR32","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/cen.14081","volume":"91","author":"M Fleseriu","year":"2019","unstructured":"Fleseriu M et al (2019) Long-term efficacy and safety of once-monthly pasireotide in Cushing\u2019s disease: A Phase III extension study. Clin Endocrinol (Oxf) 91(6):776\u2013785. https:\/\/doi.org\/10.1111\/cen.14081","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2572_CR33","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s12020-018-1675-4","volume":"62","author":"F Ceccato","year":"2018","unstructured":"Ceccato F et al (2018) Metyrapone treatment in Cushing\u2019s syndrome: a real-life study. Endocrine 62(3):701\u2013711. https:\/\/doi.org\/10.1007\/s12020-018-1675-4","journal-title":"Endocrine"},{"key":"2572_CR34","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-20-0066","author":"M Minnetti","year":"2020","unstructured":"Minnetti M, Hasenmajer V, Pofi R, Venneri MA, Alexandraki KI, Isidori AM (2020) Fixing the broken clock in adrenal disorders: Focus on glucocorticoids and chronotherapy. BioScientifica Ltd. https:\/\/doi.org\/10.1530\/JOE-20-0066","journal-title":"\u00a0BioScientifica Ltd"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02572-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-025-02572-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02572-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T04:31:47Z","timestamp":1753936307000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-025-02572-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["2572"],"URL":"https:\/\/doi.org\/10.1007\/s40618-025-02572-x","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"27 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants involved in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}